Regenxbio Inc (RGNX) is destined for greater heights as its last quarter sales were 24,200 K

A new trading day began on Friday, with Regenxbio Inc (NASDAQ: RGNX) stock price down -5.05% from the previous day of trading, before settling in for the closing price of $8.72. RGNX’s price has ranged from $8.44 to $28.80 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 72.63%. Meanwhile, its annual earnings per share averaged 21.64%. With a float of $44.85 million, this company’s outstanding shares have now reached $49.53 million.

The extent of productivity of a business whose workforce counts for 344 workers is very important to gauge. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.

Regenxbio Inc (RGNX) Insider Updates

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.47%, while institutional ownership is 90.27%. The most recent insider transaction that took place on Oct 01 ’24, was worth 101,052. In this transaction Director of this company sold 10,000 shares at a rate of $10.11, taking the stock ownership to the 11,286 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Director sold 10,000 for $11.56, making the entire transaction worth $115,588. This insider now owns 11,286 shares in total.

Regenxbio Inc (RGNX) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 21.64% per share during the next fiscal year.

Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators

Here are Regenxbio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.62.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -0.72 in one year’s time.

Technical Analysis of Regenxbio Inc (RGNX)

The latest stats from [Regenxbio Inc, RGNX] show that its last 5-days average volume of 1.73 million was superior to 0.66 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 18.56%. Additionally, its Average True Range was 0.82.

During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 0.28%, which indicates a significant decrease from 0.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.85% in the past 14 days, which was higher than the 70.00% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $9.73, while its 200-day Moving Average is $13.62. Now, the first resistance to watch is $8.65. This is followed by the second major resistance level at $9.02. The third major resistance level sits at $9.21. If the price goes on to break the first support level at $8.09, it is likely to go to the next support level at $7.89. Assuming the price breaks the second support level, the third support level stands at $7.52.

Regenxbio Inc (NASDAQ: RGNX) Key Stats

With a market capitalization of 389.53 million, the company has a total of 49,545K Shares Outstanding. Currently, annual sales are 90,240 K while annual income is -263,490 K. The company’s previous quarter sales were 24,200 K while its latest quarter income was -59,600 K.